Table 2.
Prevalence of HPV-DNA detection in semen of both the control arm and non-vaccine sensitive patients.
| Time-point | Seronegative VSP (N = 30) |
NVSP (N = 88) |
P value (NVSP vs seronegative VSP) |
Seroconverted VSP (N = 19) |
P value (Seroconverted VSP vs seronegative VSP) |
P value (Seroconverted VSP vs NVSP) |
|---|---|---|---|---|---|---|
| t0 | 30 (100%) | 88 (100%) | 1 | 19 (100%) | 1 | 1 |
| t6 | 26 (87%) | 79 (90%) | 0.74 | 16 (84%) | 0.14 | 0.44 |
| t12 | 22 (73%) | 61 (69%) | 0.82 | 8 (42%) | 0.039 | 0.034 |
| t18 | 10 (33%) | 30 (34%) | 0.99 | 1 (5%) | 0.034 | 0.011 |
| t24 | 7 (23%) | 17 (19%) | 0.61 | 0 (0%) | 0.034 | 0.034 |
Abbreviations: t0: recruitment; t6, t12, t18, t24: 6, 12, 18 and 24 months from recruitment respectively; VSP: vaccine sensitive patients; NVSP: nonvaccine-sensitive patients. Significance: bold values = P < 0·05.